Antibody-Drug Conjugates in Triple Negative Breast Cancer

KESKİNKILIÇ M., Sacks R.

Clinical Breast Cancer, vol.24, no.3, pp.163-174, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 3
  • Publication Date: 2024
  • Doi Number: 10.1016/j.clbc.2024.01.008
  • Journal Name: Clinical Breast Cancer
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.163-174
  • Keywords: TNBC, ADC, Trop-2, Sacituzumab govitecan, Trastuzumab deruxtecan
  • Dokuz Eylül University Affiliated: Yes

Abstract

Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.